Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
4.760
+0.060 (1.28%)
At close: Aug 26, 2025, 4:00 PM
4.820
+0.060 (1.26%)
After-hours: Aug 26, 2025, 5:42 PM EDT
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2024. The number of employees decreased by 9 or -45.00% compared to the previous year.
Employees
11
Change (1Y)
-9
Growth (1Y)
-45.00%
Revenue / Employee
n/a
Profits / Employee
-$2,642,912
Market Cap
15.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11 | -9 | -45.00% |
| Dec 31, 2023 | 20 | 5 | 33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | 11 | 3 | 37.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLRB News
- 12 days ago - Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 19 days ago - Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 - GlobeNewsWire
- 7 weeks ago - Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 2 months ago - Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement - GlobeNewsWire
- 2 months ago - Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) - GlobeNewsWire
- 2 months ago - Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - GlobeNewsWire